Sonexa

Dexamethasone Phosphate

Ophthalmic Solution & Ointment

Compositions :

Sonexa Ophthalmic Solution : Each ml contains Dexamethasone Sodium Phosphate USP equivalent to Dexamethasone Phosphate 1 mg.

Preservative: Benzalkonium Chloride.

Sonexa Ophthalmic Ointment : Each gram ointment contains Dexamethasone Sodium Phosphate USP equivalent to Dexamethasone Phosphate 0.5 mg.

Preservative: Methylparaben & Propylparaben.

Indications :

Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, keratitis, iritis, scleritis, corneal injury from chemical or thermal burns, or penetration of foreign bodies.

Dosage & administration:

Sonexa Ophthalmic Solution : Instill one drop into the conjunctival sac every hour during the day and every two hours during the night as initial therapy. When a favourable response is observed, reduce dosage to one drop every four hours. Later, further reduction in dosage to one drop three or four times daily may suffice to control symptoms.

Sonexa Ophthalmic Ointment : Apply a thin coating of ointment 3 or 4 times a day. When a favorable response is observed, reduce the number of daily applications to twice, and later to once a day as maintenance dose if this is sufficient to control symptoms.

Side effects :

A slight burning sensation may occur for a short time after instilling the drops into the eye. After several weeks of administration to predisposed patients there may be reversible increase in intraocular pressure. Regular pressure checks are advisable. Systemic adverse reactions may also occur after long-term topical application of corticosteriods in children. Others include cataract and corneal softening.

Contraindications :

Patients wearing contact lenses, herpes simplex & other virus conditions, mycosis, glaucoma, newborn babies, fungal diseases of ocular or auricular structures, hypersensitivity to any component of this product including sulfites.

Precaution & warning :

- If no improvement is observed after 7-8 days, other therapeutic measures should be considered.
- Corticosteroids may mask, activate or exacerbate eye infections.
- Due to the risk of systemic response the administration to children under 2 years and to hyper or hypotonics is not advisable.
- During treatment the intra-ocular pressure should be measured regularly.
- Prolonged use may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior sub-capsular cataract formation.
- Patients wearing contact lenses must not use the drops during the time the lenses are worn.

Use in pregnancy and lactation:

It should only be administered during pregnancy if the potential benefit exceeds the foreseeable risk to the fetus (Pregnancy Category C). It should be given in lactating mother if clearly indicated by the physician.

Storage :

- Store below 30°C temperature in a dry place, protect from light.
- Do not use for longer than 30 days after first opening.
- Keep out of the reach of children.

Packing :

Sonexa Ophthalmic Solution: Each LDPE dropper bottle contains 5 ml Sterile Eye Drops.

Sonexa Ophthalmic Ointment: Each tube contains 3g Sterile Ophthalmic Ointment.

ARISTOVISION

Manufactured by:
ARISTOPHARMA LTD.
GAZIPUR, BANGLADESH

20004563/02